Humanized anti-ACTH antibodies and use thereof
View Patent ↗The present invention is directed to antibodies and fragments thereof having binding specificity for ACTH. Embodiments of this invention relate to the binding fragments of antibodies described herein, comprising the sequences of the V H , V L and/or CDR polypeptides described herein, and the polynucleotides encoding them. The invention also contemplates anti-ACTH antibodies and binding fragments thereof conjugated to one or more functional or detectable moieties. The invention further contemplates methods of making said anti-ACTH antibodies and binding fragments thereof. Embodiments of the invention also pertain to the use of anti-ACTH antibodies and binding fragments thereof for the diagnosis, assessment, prevention and treatment of diseases and disorders associated with ACTH, such as CAH, FGD, Cushing's Disease, Cushing's Syndrome, Parkinson's disease, obesity, diabetes, sleep disorders, depression, anxiety disorders, cancer, muscle atrophy, hypertension, hyperinsulinemia, cognitive dysfunction, Alzheimer's disease, galactorrhea, stress related conditions, cardiac conditions, metabolic syndrome, hyperaldosteronism, Conn's syndrome and familial hyperaldosteronism.
1. An anti-human adrenocorticotrophic hormone (ACTH) antibody or antibody fragment comprising the heavy chain CDR1, CDR2, and CDR3 polypeptides of SEQ ID NO: 404; SEQ ID NO: 406; and SEQ ID NO: 408, and the light chain CDR1, CDR2, and CDR3 polypeptides of SEQ ID NO: 424; SEQ ID NO: 426; and SEQ ID NO: 428.
2. An anti-human adrenocorticotrophic hormone (ACTH) antibody or antibody fragment according to claim 1 that is humanized or chimerized.
3. An anti-human ACTH antibody or antibody fragment according to claim 1 , wherein said antibody or antibody fragment is humanized.
4. The anti-human ACTH antibody of claim 1 , which comprises a variable heavy chain having at least 90% identity to the polypeptide of SEQ ID NO: 402 and/or which comprises a variable light chain having at least 90% identity to the polypeptide of SEQ ID NO: 422, or comprises said variable light chain and said variable heavy chain.
5. The anti-human ACTH antibody of claim 1 , which comprises a heavy chain having at least 90% identity to the polypeptide of SEQ ID NO: 401 and/or which comprises a light chain having at least 90% identity to the polypeptide of SEQ ID NO: 421, or comprises said light chain and said heavy chain.
6. The anti-human ACTH antibody of claim 1 , which comprises or consists of the variable heavy chain of SEQ ID NO: 402 and the variable light chain of SEQ ID NO: 422, or comprises or consists of the heavy chain of SEQ ID NO: 401 and the light chain of SEQ ID NO: 421.
7. The anti-human ACTH antibody or antibody fragment of claim 1 , wherein the antibody or antibody fragment
(i) is selected from the group consisting of scFvs, Fab fragments, Fab′ fragments, monovalent antibody fragments, and F(ab′)2 fragments; or
(ii) the antibody comprises an unmodified IgG1, IgG2, IgG3, or IgG4 constant domain or
(iii) the antibody or antibody fragment comprises an IgG1, IgG2, IgG3, or IgG4 constant domain that has been modified to alter at least one of effector function, half-life, proteolysis, or glycosylation.
8. A composition comprising at least one anti-human ACTH antibody or antibody fragment according to claim 1 .
9. The anti-human ACTH antibody of claim 1 , which comprises a variable heavy chain having at least 95% identity to the polypeptide of SEQ ID NO: 402 and/or which comprises a variable light chain having at least 95% identity to the polypeptide of SEQ ID NO: 422.
10. The anti-human ACTH antibody of claim 1 , which comprises a variable heavy chain polypeptide of SEQ ID NO: 402 and/or which comprises a variable light chain polypeptide of SEQ ID NO: 422.
11. The anti-human ACTH antibody of claim 1 , which consists of the heavy chain of SEQ ID NO: 401 and the light chain of SEQ ID NO: 421.